• Explore /
  • Poster
  • / REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC).

REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC).

Abstract Poster

Authors

null

Yukiya Narita

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Yukiya Narita , Hirokazu Shoji , Sadayuki Kawai , Takuro Mizukami , Michio Nakamura , Toshikazu Moriwaki , Takeharu Yamanaka , Yu Sunakawa , Hisato Kawakami , Tomohiro Nishina , Toshihiro Misumi , Yu Yamashige , Akira Yamashige , Kei Muro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000032182

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr TPS178)

DOI

10.1200/JCO.2019.37.4_suppl.TPS178

Abstract #

TPS178

Poster Bd #

N10

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Gastrointestinal Cancers Symposium

REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).

REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC).

First Author: Tomohiro Matsushima

First Author: Haeseong Park

First Author: Helena Anna Taflin

First Author: Ewald Woell